Skip to main content

Table 1 Patient characteristics and clinical history at baseline

From: Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

  Present study Registration study
Number of patients (N) 217 253
Gender, n (%)
 Male 183 (84) NR
 Female 34 (16) NR
Age, years
 Median (IQR) 69 (62–76) NR
  < 65, n (%) 73 (34) 135 (53)
  ≥ 65, n (%) 144 (66) 118 (47)
ECOG PS, n (%)
 0 101 (47) 72 (28)
 1 100 (46) 181 (72)
  ≥ 2 16 (7) 0 (0)
Creatinine clearance, n (%)
  > 60 125 (58) 134 (54)
 40–60 75 (35) 104 (42)
  < 40 17 (8) 10 (4)
Number of metastatic sites, n (%)
 1 site 127 (58) 62 (25)
  ≥ 2 sites 90 (42) 191 (75)
Visceral involvement, n (%) 115 (53) 187 (74)
Metastatic sites, n (%)
 Lymph nodes only 103 (47) NR
 Liver 47 (22) NR
 Lungs 70 (32) NR
 Bone 79 (36) NR
 Brain 2 (1) NR
 Other tissue (not visceral) 32(15) NR
Prior pelvic irradiation, n (%) 16 (7) 57 (23)
Prior therapy with platinum-based regimen, n (%)
 Cisplatin 122 (56) 164 (65)
 Carboplatin 91 (42) 75 (30)
 Other platinum combination 4 (2) 14 (5)
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, IQR interquartile range, NR not reported